Rebecca E. Garris

发表

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Xuelin Huang, Guillermo Garcia-Manero, Gautam Borthakur, 2016, British journal of haematology.

Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, American journal of hematology.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015, Haematologica.

Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014, American journal of hematology.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010, Blood.

Final results of a single institution experience with a pediatric‐based regimen, the augmented Berlin–Frankfurt–Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper‐CVAD regimen

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016, American journal of hematology.

Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2014, Cancer.

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial

M. Konopleva, Z. Estrov, D. Marin, 2017, JAMA oncology.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.

M. Konopleva, Z. Estrov, H. Kantarjian, 2015, The Lancet. Oncology.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2011 .

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, The Lancet. Oncology.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2023, The Lancet. Haematology.

The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience

M. Konopleva, H. Kantarjian, T. Kadia, 2014, Leukemia.

Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant

M. Konopleva, H. Kantarjian, T. Kadia, 2020, Acta Haematologica.

Inotuzumab Ozogamicin (IO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients (pts) and as Salvage Therapy for Adult with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2015 .

Poor outcomes associated with +der(22)t(9;22) and −9/9p in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Significance of recurrence of minimal residual disease detected by multi‐parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, American journal of hematology.

Phase II study of the hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with CD-20 positive ALL.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2014 .

Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood advances.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival

M. Konopleva, Z. Estrov, H. Kantarjian, 2019, American journal of hematology.

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B‐cell acute lymphoblastic leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2017, Cancer.

Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

G. Garcia-Manero, J. Cortes, K. Patel, 2016, Blood.

Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2022, American journal of hematology.

Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.

Z. Estrov, H. Kantarjian, J. Cortes, 2013, Blood.

Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma

M. Konopleva, H. Kantarjian, F. Ravandi, 2020, American journal of hematology.

Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1

K. Patel, F. Ravandi, E. Jabbour, 2023, American journal of hematology.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, The Lancet. Haematology.

Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib

P. A. Futreal, M. Konopleva, H. Kantarjian, 2022, Leukemia.

Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

G. Garcia-Manero, Xuelin Huang, F. Ravandi, 2023, American journal of hematology.

Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Cancer.

Phase 2 study of hyper‐CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia

M. Konopleva, Z. Estrov, H. Kantarjian, 2020, American journal of hematology.

Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2015, Cancer.

Inotuzumab Ozogamicin In Combination With Low-Intensity Chemotherapy (Mini-hyper-CVD) As Frontline Therapy For Older Patients (≥60 years) With Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013 .

Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Cancer.

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

J. Radich, J. Pritchard, M. Konopleva, 2020, Blood Cancer Journal.

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

M. Andreeff, H. Kantarjian, J. Cortes, 2010 .

Hyper‐CVAD plus nelarabine in newly diagnosed adult T‐cell acute lymphoblastic leukemia and T‐lymphoblastic lymphoma

M. Konopleva, G. Garcia-Manero, J. Cortes, 2018, American journal of hematology.

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013, Cancer.

A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

K. Baggerly, M. Konopleva, Wenbin Liu, 2015, Clinical Cancer Research.

Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients (pts) with CD-20 Positive Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2015 .

Prognostic impact of CD20 and CD25 expression in patients with Philadelphia-positive (Ph + ) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2010 .

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

H. Kantarjian, J. Cortes, F. Ravandi, 2009 .

Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2016, British journal of haematology.

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2011 .

Detection of Minimal Residual Leukemia Predicts the Outcome of Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy

Z. Estrov, H. Kantarjian, J. Cortes, 2011 .

Combination of the hyperCVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Cancer.

Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2021, Cancer.

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2018, Blood.

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, Cancer.

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Journal of Clinical Oncology.

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2023, Journal of Hematology & Oncology.

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2021, Blood.

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2020 .

A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia

M. Konopleva, F. Ravandi, E. Jabbour, 2021, Blood.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Clinical characteristics and outcomes of previously untreated patients with adult onset T‐acute lymphoblastic leukemia and T‐lymphoblastic lymphoma with hyper‐CVAD based regimens

M. Konopleva, Z. Estrov, H. Kantarjian, 2017, American journal of hematology.

Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2019, Blood.

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2010 .

Final Report Of Single-Center Study Of Chemotherapy Plus Dasatinib For The Initial Treatment Of Patients With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2013 .

Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2012 .

Phase II Study Of Combination Of Hyper-CVAD With Ponatinib In Front Line Therapy Of Patients (pts) With Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2008 .

Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2016 .

Phase 2 Trial of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Blood.

Chemotherapy-Free Combination of Blinatumomab and Ponatinib in Adults with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updates from a Phase II Trial

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Blood.

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

A Phase II Study of Low-Intensity Chemotherapy (Mini-Hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

H. Kantarjian, F. Ravandi, E. Jabbour, 2023, Blood.